Zongertinib showed a 71% overall response rate and 93% disease control rate in HER2-mutated NSCLC patients, with a median PFS of 12.4 months. No cases of interstitial lung disease were reported ...

Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition ...

The Ventana TROP2 RxDx Device, a computational pathology CDx, received FDA breakthrough designation for non–small cell lung cancer. AI-based image analysis in the device offers superior diagnostic ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes but increases treatment-related toxicity. Up-front stereotactic radiosurgery ...

Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in previously treated patients with advanced non-small cell lung cancer ...